Organogenesis Holdings Inc. (2PQ.F)
| Previous close | 2.1800 |
| Open | 2.3200 |
| Bid | 2.3200 x 0 |
| Ask | 2.3600 x 0 |
| Day's range | 2.3200 - 2.3200 |
| 52-week range | 1.7600 - 4.2400 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 330.482M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | 58.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. Management will host a conference call at 5:00 p.m. Eastern Time on May 9th to
- GlobeNewswire
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted. “We are very pleased with t
- GlobeNewswire
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2023. Fourth Quarter 2023 Financial Results Summary: Net revenue of $99.7 million for the fourth quarter of 2023, a decrease of
